Last reviewed · How we verify
Penicillin O (ALMECILLIN)
Penicillin O (generic name: ALMECILLIN) is a almecillin drug. It is currently in Phase 2 development.
Almecillin works by inhibiting bacterial cell wall synthesis.
Almecillin, also known as Penicillin O, is a small molecule antibiotic in the almecillin class. Unfortunately, there is limited information available on this medication. It is not clear what specific target it binds to or what its approved indications are. Almecillin's commercial status and safety considerations are also unknown. Further research is needed to fully understand this medication.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ALMECILLIN |
|---|---|
| Drug class | almecillin |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like houses, and the bacteria are like construction workers trying to build new houses. Almecillin is like a tool that prevents the construction workers from building the houses, effectively stopping the bacteria from growing and multiplying.
Approved indications
Common side effects
Key clinical trials
- A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia (PHASE3)
- Inpatient Penicillin Delabeling for Low-Risk Patients (PHASE4)
- MENJAGA: Continuous Quality Improvement for Antenatal HIV, Syphilis and Hepatitis B Testing in Indonesia (NA)
- Preventing Congenital Syphilis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Penicillin O CI brief — competitive landscape report
- Penicillin O updates RSS · CI watch RSS
Frequently asked questions about Penicillin O
What is Penicillin O?
How does Penicillin O work?
What is the generic name of Penicillin O?
What drug class is Penicillin O in?
What development phase is Penicillin O in?
Related
- Drug class: All almecillin drugs
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing